Multiple Sclerosis | China In-Depth | China | 2019


Multiple Sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in the country. Two approved disease-modifying therapies (DMTs)—IFN-β-1b (Bayer’s Betaferon) and teriflunomide (Sanofi’s Aubagio)—and immunosuppressants such as methotrexate, mitoxantrone, rituximab, azathioprine are used to treat MS in China. The late-phase MS pipeline in China includes two S1PR modulators(siponimod [Novartis’s Mayzent] and the recently approved fingolimod [Novartis’s Gilenya]) and an anti-CD52 MAb(alemtuzumab [Sanofi’s Lemtrada]). Siponimod is under regulatory review by the NMPA, while alemtuzumab is eligible for priority review. The NMPA is focused on granting fast-track designations to therapies that address urgent clinical need in China, thus allowing such agents to move directly to the market filing stage based on foreign clinical trial data. Therefore, current MS agents in China are likely to witness stiff competition in the next few years because of the expected launch of new therapies.

  • How large is China’s drug-treatable MS population, and how will drug-treatment rate change during the forecast period?
  • Which are the most commercially relevant drugs in China’s MS market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
  • What are the key market access considerations for key therapies in the MS pipeline in China? What sales/uptake could they secure in MS? What are interviewed experts’ opinions on the key emerging therapies?
  • What are the key drivers and constraints in the Chinese MS market, and how will the market evolve over the forecast period?


China In-Depth: Comprehensive market intelligence providing world-class epidemiology and keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Release date

July 2019



Primary Research

Qualitative and quantitative insights driven by five country-specific interviews with thought-leading neurologists, supported by survey data collected for this and other DRG research.


Diagnosed prevalence of MS by disease subtype. Clinically relevant and market-relevant drug-treatable populations.


Ten-year, annualized, drug-level sales and patient shares of key MS therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.


Phase III/PR: 2 drugs; coverage of select early-phase products.

Login to access report

launch Related Market Assessment Reports